Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TBK1 | Q9UHD2 | 14/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 8/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907061 | 0.99 | TTR (0.53) | TTRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2907068 | 0.99 | TTR (0.53) | TTRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL11365313 | 0.90 | KDM4E (0.49) | TTRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2907058 | 0.88 | TTR (0.46) | TTRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL11356857 | 0.86 | TTR (0.56) | TTRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL11549501 | 0.85 | MEN1 (0.70) | TTRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2904833 | 0.85 | KDM4E (0.56) | TTRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2901859 | 0.83 | TBK1 (0.58) | TTRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL11108156 | 0.83 | MAOB (0.56) | TTRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2907432 | 0.82 | TBK1 (0.56) | TTRNPC1RAB9ATBK1IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042923-A1 | Method of Treating Tumors with Azaxanthones | SEMOV ALEXANDRE | 2009-02-12 | — | — | US | claimed |
| US-20070135473-A1 | Method of treating tumors with azaxanthones | SUPRATEK PHARMA, INC. | 2007-06-14 | — | — | US | claimed |
| US-4143042-A | ANTIALLERGENS, BRONCHODILATOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1979-03-06 | — | — | US | claimed |
| EP-1968981-B1 | AZAXANTHONES AND USE THEREOF FOR TREATING TUMORS | SUPRATEK PHARMA INC (CA) | 2010-08-18 | — | — | EP | disclosed |
| US-7772255-B2 | Method of treating tumors with azaxanthones | SUPRATEK PHARMA, INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20090042923-A1 | Method of Treating Tumors with Azaxanthones | SEMOV ALEXANDRE | 2009-02-12 | — | — | US | disclosed |
| US-20070135473-A1 | Method of treating tumors with azaxanthones | SUPRATEK PHARMA, INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135473-A1 | Method of treating tumors with azaxanthones | S100A4, S100B, S100P | TTR 1926/4885NPC1 4456/4885RAB9A 2400/4885 |
| US-20090042923-A1 | Method of Treating Tumors with Azaxanthones | S100A4, S100P, S100B | TTR 1495/4885NPC1 4429/4885RAB9A 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.